Acorda Therapeutics, Inc.
ACORQ
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -62.83% | -1,237.61% | 35.84% | 79.90% | 31.39% |
| Total Depreciation and Amortization | -88.85% | -1.44% | 1.58% | -6.27% | -7.28% |
| Total Amortization of Deferred Charges | 19.40% | 11.67% | 19.64% | 10.15% | 10.52% |
| Total Other Non-Cash Items | 308.34% | 1,125.70% | -117.98% | -112.21% | 40.76% |
| Change in Net Operating Assets | -1,205.76% | -324.38% | 233.34% | -367.34% | -86.01% |
| Cash from Operations | -187.62% | -133.29% | 513.70% | 20.38% | 48.54% |
| Capital Expenditure | -- | -- | -714.81% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -135.77% | -46.67% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -195.88% | -92.86% | 51.24% | 141.22% | 205.43% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -192.99% | -128.30% | 412.76% | 23.79% | 49.73% |
